Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks .

What is Aeterna Zentaris' stock price target for 2024?

1 brokers have issued 12 month price targets for Aeterna Zentaris' shares. Their AEZS share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 669.2% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts .

How have AEZS shares performed in 2024?

Aeterna Zentaris' stock was trading at $1.86 on January 1st, 2024. Since then, AEZS stock has increased by 4.8% and is now trading at $1.95. View the best growth stocks for 2024 here .

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a decrease in short interest in March. As of March 31st, there was short interest totaling 21,700 shares, a decrease of 25.7% from the March 15th total of 29,200 shares. Based on an average trading volume of 17,300 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.5% of the shares of the company are short sold. View Aeterna Zentaris' Short Interest .

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AEZS earnings forecast .

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.60 million. Aeterna Zentaris had a negative net margin of 368.01% and a negative trailing twelve-month return on equity of 63.20%.

When did Aeterna Zentaris' stock split?

Shares of Aeterna Zentaris reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN) , Pennsylvania Real Estate Investment Trust (PEI) , CBL & Associates Properties (CBL) , Gran Tierra Energy (GTE) , CNBX Pharmaceuticals (CNBX) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Novan (NOVN) and Washington Prime Group (WPG) .

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free AEZS Stock Alerts

$1.95

-0.03 (-1.52%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.95
▼
$2.01
50-Day Range: $1.71
▼
$2.19
52-Week Range: $1.36
▼
$3.38

Volume: 5,967 shs
Average Volume: 16,470 shs
Market Capitalization: $9.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Aeterna Zentaris alerts:

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 669.2% Upside
$15.00 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.45 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aeterna Zentaris has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Aeterna Zentaris has been sold short.
Short Interest Ratio / Days to Cover
Aeterna Zentaris has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aeterna Zentaris has recently decreased by 25.68%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aeterna Zentaris does not currently pay a dividend.
Dividend Growth
Aeterna Zentaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AEZS.

2.6

News and Social Media Coverage

News Sentiment
Aeterna Zentaris has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for AEZS on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.10% of the stock of Aeterna Zentaris is held by insiders.
Percentage Held by Institutions
Only 0.73% of the stock of Aeterna Zentaris is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aeterna Zentaris is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aeterna Zentaris is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aeterna Zentaris has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AEZS Stock News Headlines

April 14, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

April 12, 2024 | americanbankingnews.com

Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Large Decline in Short Interest

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

April 6, 2024 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Stock Price Passes Above 200-Day Moving Average of $1.93

April 6, 2024 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Shares Pass Above 200 Day Moving Average of $1.93

April 6, 2024 | americanbankingnews.com

Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com

April 2, 2024 | theglobeandmail.com

Auxly Cannabis Group: Top 10 Undervalued Healthcare Sector Stocks on TSX (XLY)

March 28, 2024 | globenewswire.com

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 27, 2024 | benzinga.com

AEterna Zentaris: Q4 Earnings Insights

March 27, 2024 | globenewswire.com

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

March 13, 2024 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

March 12, 2024 | globenewswire.com

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

February 28, 2024 | thestreet.com

Aeterna Zentaris Inc.

February 26, 2024 | globenewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

February 15, 2024 | globenewswire.com

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

November 14, 2023 | morningstar.com

AEterna Zentaris Inc AEZS

November 9, 2023 | msn.com

Aeterna Zentaris GAAP EPS of -$0.85

November 9, 2023 | finance.yahoo.com

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

November 6, 2023 | theglobeandmail.com

AEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)

October 30, 2023 | theglobeandmail.com

AEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)

October 11, 2023 | finance.yahoo.com

Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

September 12, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)

September 5, 2023 | finance.yahoo.com

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | theglobeandmail.com

Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)

August 10, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)

August 9, 2023 | finance.yahoo.com

Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

See More Headlines

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AEZS
CUSIP: N/A
CIK: 1113423
Web: www.zentaris.com
Phone: (418) 652-8525
Fax: 418-948-9191
Employees: 11
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +661.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,550,000.00
Net Margins: -368.01%
Pretax Margin: -367.99%
Return on Equity: -63.20%
Return on Assets: -37.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.01
Quick Ratio: 8.00

Sales & Book Value

Annual Sales: $4.50 million
Price / Sales: 2.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.75 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 4,860,000
Free Float: 4,851,000
Market Cap: $9.57 million
Optionable: No Data
Beta: 1.57

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Klaus Paulini Ph.D.
President, CEO & Executive Director
Mr. Giuliano La Fratta
Senior VP of Finance & CFO
Dr. Michael Teifel Ph.D.
Senior VP of Non-Clinical Development & Chief Scientific Officer
Dr. Nicola Ammer M.D.
Chief Medical Officer & Senior VP of Clinical Development
Dr. Matthias Gerlach
Senior Vice President Manufacturing & Supply Chain

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Bought 8 shares on 2/15/2024
Ownership: 0.000%

View All Institutional Transactions

AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.
What is Aeterna Zentaris' stock price target for 2024?: 1 brokers have issued 12 month price targets for Aeterna Zentaris' shares. Their AEZS share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 669.2% from the stock's current price.
View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts.
How have AEZS shares performed in 2024?: Aeterna Zentaris' stock was trading at $1.86 on January 1st, 2024. Since then, AEZS stock has increased by 4.8% and is now trading at $1.95.
View the best growth stocks for 2024 here.
Are investors shorting Aeterna Zentaris?: Aeterna Zentaris saw a decrease in short interest in March. As of March 31st, there was short interest totaling 21,700 shares, a decrease of 25.7% from the March 15th total of 29,200 shares. Based on an average trading volume of 17,300 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.5% of the shares of the company are short sold.
View Aeterna Zentaris' Short Interest.
When is Aeterna Zentaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AEZS earnings forecast.

How were Aeterna Zentaris' earnings last quarter?: Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.60 million. Aeterna Zentaris had a negative net margin of 368.01% and a negative trailing twelve-month return on equity of 63.20%.
When did Aeterna Zentaris' stock split?: Shares of Aeterna Zentaris reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Aeterna Zentaris own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).
How do I buy shares of Aeterna Zentaris?: Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Aeterna Zentaris MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aeterna Zentaris Stock (NASDAQ:AEZS)

AEZS Stock Price History

AEZS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

AEZS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™